Prostamax
A Russian prostate bioregulator men run in short courses for night-time trips and a dull ache. Animal data only; get the real workup first.
What it is
Prostamax is a four-amino-acid Khavinson bioregulator aimed at prostate tissue. Men over 45 with the familiar picture, up twice a night, a weaker stream, a dull ache after sitting, run it in 10 to 20 day courses hoping for a calmer prostate. In animal models of prostatitis and enlargement it reduced inflammation; in men it has never been tested.
The men who try it are the ones with mild enlargement or chronic prostatitis symptoms who have had the proper workup, a PSA and an exam, and either do not want the side effects of the standard medicines or want something alongside them. It is a bioregulator: a fragment peptide proposed to nudge gene expression in one tissue, with no receptor or dose-response curve to speak of. It is not an antibiotic for a bacterial prostatitis, it does not shrink a large prostate the way finasteride does, and it must not be the reason a man puts off an exam, because the same symptoms can be infection or cancer.
If it helps, it is subtle and shows after the course ends: fewer night-time trips and less pelvic ache two to four weeks later, in the men who report anything. There is nothing to feel during the course and no acute effect to adjust to. If a 20-day course changes nothing within six weeks, repeating it sooner will not either; the schedule is a course every few months, two or three a year, because any effect is meant to carry on long after the course ends.
Our doses are 200 mcg to start, 500 mcg standard and 1 mg at most, once a day, IM or subQ, for 10 to 20 days (up to 30), then a few months off before the next course. A 20 mg vial in 2 ml is 10 mg/ml, so 500 mcg is 5 units on an insulin syringe. A 20-day course at 500 mcg uses 10 mg, half the vial, and the mix keeps about four weeks, so the other half is wasted unless you run the 1 mg dose, which uses the vial exactly and has no evidence of doing more. Vendor protocols that run it daily for 8 to 16 weeks have nothing behind them; the animal work used 15 to 60 day courses and the Russian convention is short.
The evidence is animal and single-source. In rat models of prostatitis and benign enlargement, Prostamax lowered inflammatory markers, reduced prostate weight and improved tissue appearance under the microscope, in work from the St Petersburg institute that developed the whole bioregulator class. There is no published human trial of any size, no independent replication, and no approval anywhere. The mechanism offered, epigenetic tuning of gene expression, is a hypothesis.
If the problem is enlargement with a weak stream, the standard medicines (alpha blockers for flow, 5-alpha-reductase inhibitors for size) are well proven and this is not in their league. If it is chronic pelvic pain, a urologist and pelvic floor work do more than any peptide. Among the bioregulators, Vesugen is the blood-vessel one and Cartalax the joint one; nothing else here targets the prostate. Prostamax is the low-risk thing to try once, after the workup, alongside whatever actually works.
What people use it for
Prostate inflammation
Early daysIn rat models of prostatitis, Prostamax lowered inflammatory markers and improved the look of the tissue under the microscope. This is the strongest finding and it is animal work from the originating institute, without independent replication or a human trial.
Enlarged prostate
Early daysIn rodent models of benign enlargement, treated animals had lower prostate weight and more normal tissue structure. No man has been studied for stream, night-time urination or prostate volume, which are the things that would matter.
How it is thought to work
Early daysThe bioregulator hypothesis is that short peptides enter the nucleus and loosen chromatin to reactivate genes that quiet down with age, here in prostate cells. Cell studies from the same group support parts of this. It is a mechanism story, not evidence of benefit.
How people use it
Safety, in brief
Things people sometimes notice
- A little redness or tenderness where you inject
- Nothing noticeable, which is the usual report
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.